Evercore Trust Company Lifted Its Philip Morris Intl (PM) Holding by $1.70 Million as Stock Price Rose; Wilsey Asset Management Position in Gilead Sciences (GILD) Lowered by $332,182

February 23, 2018 - By Adrian Mccoy

Evercore Trust Company increased its stake in Philip Morris Intl Inc (PM) by 2% based on its latest 2017Q3 regulatory filing with the SEC. Evercore Trust Company bought 15,323 shares as the company’s stock rose 10.69% with the market. The institutional investor held 782,252 shares of the farming and seeds and milling company at the end of 2017Q3, valued at $86.84M, up from 766,929 at the end of the previous reported quarter. Evercore Trust Company who had been investing in Philip Morris Intl Inc for a number of months, seems to be bullish on the $162.97 billion market cap company. The stock increased 1.88% or $1.94 during the last trading session, reaching $104.92. About 2.32 million shares traded. Philip Morris International Inc. (NYSE:PM) has risen 16.65% since February 23, 2017 and is uptrending. It has underperformed by 0.05% the S&P500.

Wilsey Asset Management Inc decreased its stake in Gilead Sciences Inc (GILD) by 3.37% based on its latest 2017Q3 regulatory filing with the SEC. Wilsey Asset Management Inc sold 4,051 shares as the company’s stock declined 8.05% while stock markets rallied. The institutional investor held 116,203 shares of the health care company at the end of 2017Q3, valued at $9.61M, down from 120,254 at the end of the previous reported quarter. Wilsey Asset Management Inc who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $104.46B market cap company. The stock increased 0.71% or $0.565 during the last trading session, reaching $79.965. About 2.80M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since February 23, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.




Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It is positive, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Cambridge Advsrs stated it has 6,894 shares or 0.21% of all its holdings. 43,234 were accumulated by Sandy Spring Bank & Trust. Commonwealth Equity Services Incorporated reported 317,465 shares. Shelter Insurance Retirement Plan has invested 1.62% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Renaissance Tech Ltd Liability Company holds 0.98% in Gilead Sciences, Inc. (NASDAQ:GILD) or 10.23M shares. Magellan Asset Management Limited invested 0% in Gilead Sciences, Inc. (NASDAQ:GILD). California-based Diligent Investors Ltd Liability Corp has invested 0.19% in Gilead Sciences, Inc. (NASDAQ:GILD). Yhb Inv Advsr reported 0.41% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Teacher Retirement System Of Texas, Texas-based fund reported 879,616 shares. Shelter Mutual has invested 1.87% in Gilead Sciences, Inc. (NASDAQ:GILD). Landscape Limited stated it has 5,375 shares. Wright Investors Service has invested 1.34% in Gilead Sciences, Inc. (NASDAQ:GILD). The Pennsylvania-based Haverford Co has invested 0.01% in Gilead Sciences, Inc. (NASDAQ:GILD). 110,415 are held by Channing Mngmt Ltd. First Manhattan owns 2.80M shares for 1.3% of their portfolio.

Wilsey Asset Management Inc, which manages about $136.59 million and $155.04 million US Long portfolio, upped its stake in Intel Corp (NASDAQ:INTC) by 29,010 shares to 247,864 shares, valued at $9.61M in 2017Q3, according to the filing.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 125 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Argus Research on Thursday, August 31. The firm has “Overweight” rating by Piper Jaffray given on Thursday, November 5. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by BMO Capital Markets on Wednesday, November 2. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Friday, October 27 by BMO Capital Markets. As per Tuesday, July 25, the company rating was maintained by Piper Jaffray. Oppenheimer maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Tuesday, October 20. Oppenheimer has “Outperform” rating and $124 target. Cowen & Co maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, September 21 with “Buy” rating. The rating was upgraded by Bank of America to “Neutral” on Monday, January 18. Cowen & Co maintained the shares of GILD in report on Wednesday, October 18 with “Buy” rating. The rating was maintained by Mizuho with “Buy” on Monday, February 5.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1. They expect $1.59 EPS, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.08B for 12.57 P/E if the $1.59 EPS becomes a reality. After $1.60 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

Since August 30, 2017, it had 0 insider purchases, and 15 sales for $56.94 million activity. Washington Robin L also sold $4.40 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. On Thursday, August 31 the insider MARTIN JOHN C sold $6.09M. Another trade for 50,000 shares valued at $3.95 million was sold by Alton Gregg H. Shares for $4.68M were sold by WILSON GAYLE E on Friday, February 9.

Since August 30, 2017, it had 0 insider buys, and 2 selling transactions for $13.44 million activity. Another trade for 108,979 shares valued at $11.81M was made by CAMILLERI LOUIS C on Tuesday, October 24.

Investors sentiment increased to 0.97 in 2017 Q3. Its up 0.09, from 0.88 in 2017Q2. It improved, as 55 investors sold PM shares while 524 reduced holdings. 112 funds opened positions while 452 raised stakes. 1.10 billion shares or 0.12% more from 1.10 billion shares in 2017Q2 were reported. First Manhattan Com holds 1% or 1.57M shares. Stock Yards Bank & Trust Trust invested 0.45% in Philip Morris International Inc. (NYSE:PM). Loring Wolcott Coolidge Fiduciary Llp Ma reported 503,195 shares. Pittenger And Anderson Inc holds 0.04% or 4,363 shares. Ariel Invs Ltd Com holds 1.12% or 870,047 shares. Community Fincl Bank Na has 0.13% invested in Philip Morris International Inc. (NYSE:PM). Genesee Valley Tru has 19,364 shares for 0.88% of their portfolio. First Interstate Fincl Bank reported 0.11% in Philip Morris International Inc. (NYSE:PM). Empirical Financial Services Llc invested in 0.05% or 1,992 shares. 13,200 are held by Independent Invsts. First City Mgmt holds 0.98% or 12,646 shares in its portfolio. Grandfield Dodd Ltd Limited Liability Company holds 14,076 shares. 1.17M were accumulated by Suntrust Banks. Staley Cap Advisers has invested 1.91% in Philip Morris International Inc. (NYSE:PM). Country Bancorporation invested in 0.26% or 52,158 shares.

Among 19 analysts covering Philip Morris International (NYSE:PM), 13 have Buy rating, 0 Sell and 6 Hold. Therefore 68% are positive. Philip Morris International had 54 analyst reports since August 24, 2015 according to SRatingsIntel. Goldman Sachs upgraded the stock to “Buy” rating in Monday, September 12 report. The firm has “Buy” rating given on Friday, August 18 by Piper Jaffray. The rating was upgraded by Goldman Sachs to “Buy” on Thursday, September 28. Bank of America maintained the stock with “Neutral” rating in Friday, October 20 report. The rating was upgraded by SBG Securities on Wednesday, July 20 to “Hold”. The firm has “Buy” rating by Cowen & Co given on Monday, August 21. SBG Securities upgraded the shares of PM in report on Friday, August 11 to “Hold” rating. The stock has “Neutral” rating by Citigroup on Friday, October 20. On Friday, September 22 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Philip Morris International Inc. (NYSE:PM) has “Buy” rating given on Thursday, January 11 by Piper Jaffray.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.